Five things for pharma marketers to know: Monday, June 12, 2017

Share this content:

1. Teva Pharmaceutical Industries received FDA approval as the first generic version of Gilead Sciences' HIV treatment Truvada on the market. (Stat)

2. The FDA rejected Coherus' marketing application for a biosimilar version of Amgen's bone marrow stimulant Neulasta. (Endpoints News)

3. A Klick Health survey of more than 1,000 American adults found that 17% of people view health sectors as the most innovative when compared to 17 other industries, including consumer electronics, telecommunications, and media and entertainment.

4. Praluent, Sanofi and Regeneron's anti-cholesterol drug, significantly reduced cholesterol in patients with diabetes when added to statin therapy, based on data from two late-stage trials. (PharmaTimes)

5. Ertugliflozin, an experimental SGLT-2 inhibitor developed by Merck and Pfizer, reduced average glucose levels when included in metformin or initial co-administration with sitagliptin, the drugmakers found in two Phase-III studies.

Share this content:
Scroll down to see the next article